Reata Pharmaceuticals shares are trading higher on continued strength after the company yesterday announced the FDA approved Prior Approval Supplement to update the drug substance specification for SKYCLARYS. Also, Ladenburg Thalmann raised its price target from $104 to $122.
Portfolio Pulse from Benzinga Newsdesk
Reata Pharmaceuticals' shares are trading higher following the FDA's approval of the Prior Approval Supplement to update the drug substance specification for SKYCLARYS. Ladenburg Thalmann has also increased its price target for the company from $104 to $122.
June 29, 2023 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reata Pharmaceuticals' stock is trading higher after the FDA approved an update for SKYCLARYS and Ladenburg Thalmann raised its price target for the company.
The FDA's approval of the Prior Approval Supplement for SKYCLARYS is a positive development for Reata Pharmaceuticals, indicating regulatory support for the company's product. This, combined with Ladenburg Thalmann's increased price target, suggests a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100